AVAnu K. Vasudevan

Anu K. Vasudevan

*This is an algorithmically generated author record based on publicly available information.

Anu K. Vasudevan has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Mohamed Rela

    The Institute of Liver Disease and Transplantation, Dr. Rela Institute and Medical Centre Chennai India

    4 shared publications
  • Ashwin Rammohan

    The Institute of Liver Disease & Transplantation, Dr.Rela Institute & Medical Centre, Bharath Institute of Higher Education & Research, Chennai, India

    3 shared publications
  • Jagadeesh Menon

    Department of Pediatric Gastroenterology, Hepatology and Nutrition, Dr Rela Institute & Medical Centre, Bharath Institute of Higher Education and Research, Chennai, India

    3 shared publications
  • Ilankumaran Kaliamoorthy

    The Institute of Liver Disease and Transplantation, Dr. Rela Institute & Medical Centre Bharath Institute of Higher Education & Research Chennai India

    2 shared publications
  • Naresh Shanmugam

    The Institute of Liver Disease and Transplantation, Dr. Rela Institute & Medical Centre Bharath Institute of Higher Education & Research Chennai India

    2 shared publications
  • Agragesh Ramani

    Molecular Biology, Acrannolife Genomics Private Limited Chennai India

    1 shared publication

Latest Publications

  • Characterizing Early Donor‐Derived cfDNA Kinetics in Stable Pediatric Living‐Donor Liver Transplant Recipients

    by Naresh Shanmugam, Avinash Ramani, Bhavani Gunasekaran, Pavan Kumar K. Bapatla, Nivethitha Jayakanthan, Ebila Yesudhasan, Mohanty Rithika, Agragesh Ramani, Anu Vasudevan, V. R. Jagadeesh Menon, et al.

    Background: Early and precise assessment of graft health is vital for pediatric liver transplant patients; however, current monitoring methods depend largely on invasive biopsies and non‐specific biochemical tests. Donor‐derived cell‐free DNA (ddcfDNA) has emerged as a promising non‐invasive biomarker for detecting graft injury, but data on its early post‐transplant kinetics, baseline levels, and the influence of donor and recipient factors in stable pediatric populations remain limited. Objective: To prospectively characterize the early postoperative patterns of ddcfDNA and explore baseline ranges in clinically stable pediatric recipients of living donor liver transplants (LDLT), while evaluating the influence of recipient and donor demographic and clinical variables on ddcfDNA dynamics for improved non‐invasive graft monitoring. Methods: In a cohort of 22 stable pediatric LDLT recipients, ddcfDNA levels were measured longitudinally using the Trunome GrafAssure assay at postoperative days 1–2, 7, 10–14, and 30–31. Concurrent liver function tests and clinical data were also collected. Statistical analyses were performed to evaluate correlations and determine the significance of the observed relationships. Results: ddcfDNA peaked on days 1–2 (~9.0%, 2.3 ng/mL), declined sharply by day 7 (~2.4%, 1.0 ng/mL), and stabilized by days 30–31 (~2.0%, 0.2 ng/mL). Liver enzymes decreased gradually. The absolute quantification values and the ddcfDNA percentage correlated with AST and ALT early post‐transplant, with associations diminishing over time. Recipient and donor characteristics did not significantly affect ddcfDNA levels. Conclusion: dd‐cfDNA demonstrates rapid postoperative clearance and stable longitudinal trends in clinically stable pediatric liver transplant recipients. The baseline values and kinetic patterns characterized provide a preliminary reference framework for future comparative studies evaluating dd‐cfDNA behavior during graft dysfunction, rejection, or other adverse events in the early postoperative and surveillance periods.

  • Long‐Term Amino Acid Homeostasis, Neurodevelopmental and Growth Profiles Following Liver Transplantation in Maple Syrup Urine Disease

    by Anu K. Vasudevan, Naresh Shanmugam, Ashwin Rammohan, Umamaheswari Balakrishnan, Jagadeesh Menon, Mohammed Asrar Ul Huq Iqbal, Gehan Mohammed Osman Mohammed, Ilankumaran Kaliamoorthy, Mohamed Rela

    Introduction: Maple syrup urine disease (MSUD) is caused by the deficiency of branched‐chain keto acid dehydrogenase (BCKAD) and, it is well described that BCKAD contributed by an allograft following liver transplantation (LT) phenotypically normalizes this inborn error of metabolism (IEM). There is, however, a paucity of data especially with regards to the neurodevelopmental aspects and catch‐up growth profiles after LT in a resource‐challenged setting. We present our series of children under 6 years of age who underwent LT for MSUD particularly focusing on their amino acid homeostasis, neurodevelopmental and somatic growth profiles.Methods: Of 580 consecutive pediatric LT (PLT) performed between January 2011 and December 2022, all children who underwent LT for MSUD were included for analysis. Data accrued included peri‐LT details, pre‐ and post‐LT metabolic profile, neurodevelopmental assessment, somatic growth evaluation, and long‐term outcomes.Results: Six children underwent LT for MSUD with a median age and weight at LT of 20.5 (IQR: 8–60) months and 10.1 (IQR: 6.7–15.8) kg, respectively. One explanted liver was used as a domino graft for Arginase deficiency. Median follow‐up period was 52.5 (IQR: 27–94) months. None had vascular or biliary complications. Following LT, all children were started on an unrestricted protein diet and had normalization of BCAA levels. Post‐LT height and weight improved by 1 SD but did not achieve the normal profile. None of the children had neuro‐deterioration and have achieved new milestones.Conclusion: This is the first‐report presenting the growth aspects, amino acid and neurodevelopmental profiles of children who underwent LT for MSUD within the socio‐economic‐cultural idiosyncrasies and constraints prevalent in our part of the world.


  • Outcomes of pediatric liver transplantation for progressive familial intrahepatic cholestasis

    by Anu K. Vasudevan, Naresh Shanmugam, Ashwin Rammohan, Joseph J. Valamparampil, Kshetra Rinaldhy, Jagadeesh Menon, Ravikumar Thambithurai, Saravanapandian Namasivayam, Ilankumaran Kaliamoorthy, Mohamed Rela

    Background: Progressive familial intrahepatic cholestasis (PFIC) is a heterogenous group of inherited hepatocellular disorders and the clinical aspects, role of liver transplantation (LT), and its outcomes remain largely unelucidated. We present our data of LT for each type of PFIC and compare their early, and long‐term outcomes, highlighting their individual differences and management strategies.Methods: Prospectively collected data over a decade (2011–2022) of children with PFIC who underwent LT was analyzed. The groups (PFIC 1–4) were compared with regard to early and long‐term outcomes including attainment of catch‐up growth.Results: Of 60 children with PFIC who underwent LT, 13, 11, 31 & 5 were of PFIC 1, 2, 3 & 4, respectively. There were no significant differences in gender, PELD scores, BMI, type of grafts, cold and warm ischemia times, intraoperative blood loss, and morbidity among the groups. Post‐LT chronic diarrhea was observed in 6 (46.1%) children with PFIC‐I, and of them, 3 (23%) developed graft steatohepatitis. Three of these children underwent total internal biliary diversion (TIBD) and on 1‐year follow‐up, their graft steatosis resolved and they attained catch‐up growth. Catch‐up growth was significantly poorer in the PFIC1 group (44.4% vs. 88%, 90%, 100% p < .001). Overall 1‐ and 5‐year patient survival of the four PFIC groups (1–4) were 69.2%, 81.8%, 96.8%, 100% & 69.2%, 81.8%, 96.8%, 100%, respectively.Conclusion: Ours is the largest to‐date series of LT for PFIC illustrating their short‐ and long‐term outcomes. While the results for the whole cohort were excellent, those after LT for PFIC1 was relatively poorer as reflected by catch‐up growth, graft steatosis, and post‐LT diarrhea, which can be optimized by the addition of TIBD during LT.


  • Managing recurrent portal steal in auxiliary liver transplantation for non‐cirrhotic metabolic liver disease

    by Anu K. Vasudevan, Naresh P. Shanmugam, Ashwin Rammohan, Mohamed Rela

    Background: APOLT has been proposed as a treatment modality for certain types of NCMLD. While the short‐term outcomes of this operation have been comparable with orthotopic LT, its long‐term outcomes have sparsely been reported. We present one such case of Citrullinemia type I who underwent APOLT and developed recurrent PS.Case Report: A 2‐year‐old male child with a diagnosis of Citrullinemia type I underwent APOLT with a left lateral segment from a split deceased donor liver, and his postoperative period was unremarkable. Ammonia‐lowering agents were stopped 1 week following the operation and the child was discharged home on a normal diet. Four years following APOLT, the child presented with altered sensorium and seizures. A diagnosis of PS was made. Subsequent to an embolization of the native liver's right anterior portal vein his sensorium improved and he remained clinically stable on a normal diet. Six years following the APOLT, the child again presented with features of acute encephalopathy. Imaging was suggestive of PS. A portal vein embolization of the native portal vein was performed and the child's clinical condition improved. At 6 months' follow‐up, the child remains well on a normal diet.Conclusions: While the early impediments in this technique may have been overcome, in the absence of any realistic clinical application gene therapy, the debate of long‐term phenotypic metabolic correction for NCMLD by APOLT needs to be revisited.